No Data
No Data
ArriVent BioPharma Advances Cancer Therapeutics Pipeline
H.C. Wainwright Maintains ArriVent BioPharma(AVBP.US) With Buy Rating, Maintains Target Price $36
Express News | HC Wainwright & Co. Reiterates Buy on ArriVent BioPharma, Maintains $36 Price Target
ArriVent BioPharma, Inc.: Promising Clinical Trials and Strategic Collaborations Drive Buy Rating
Express News | Hhlr Advisors, Ltd. Reports Passive Stake of 13.4% in Arrivent Biopharma Inc as of September 30, 2024- SEC Filing
ArriVent Biopharma Reports Q3 EPS (61c), Consensus ($1.07)
Unlock the Full List